...
首页> 外文期刊>Investigational new drugs. >Irinophore C (TM), a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities
【24h】

Irinophore C (TM), a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities

机译:伊立替康的脂质纳米颗粒制剂Irinophore C(TM)消除了伊立替康在临床毒性大鼠模型中的胃肠道作用

获取原文
获取原文并翻译 | 示例

摘要

Irinotecan is a water-soluble camptothecin derivative with clinical activity against colorectal and small cell lung cancers and is currently a standard of care therapeutic in the treatment of colorectal cancer in combination with 5-fluorouracil. One of the major clinical issues limiting the use of irinotecan is gastrointestinal toxicity manifested as life-threatening diarrhea which is reported in up to 45 % of treated patients. The studies summarized here tested, in a rat model of irinotecan-associated gastro-intestinal toxicity, whether a lipid nanoparticle formulation of irinotecan, Irinophore C (TM), mitigated early-onset or late-onset diarrhea when given at doses equivalent to unformulated irinotecan that engenders both early- and late-onset diarrhea. Specifically, rats administered intravenously on two consecutive days with unformulated irinotecan at 170 mg/kg then 160 mg/kg experienced transient early-onset diarrhea after each administration and then experienced significant late-onset diarrhea peaking 4 days after treatment. Irinophore C (TM) given at the identical dose and schedule did not elicit either early- or late-onset diarrhea in any animals. When Irinophore C (TM) was combined with 5-fluorouracil there was also no early- or late-onset diarrhea observed. Histopathological analysis of the gastro-intestinal tract confirmed that the effects associated with irinotecan treatment were absent in rats given Irinophore C (TM) at the identical dose. Pharmacokinetic analysis demonstrated significantly higher systemic concentrations of irinotecan in rats given the nanoparticle formulation compared to those given unformulated irinotecan. These results demonstrate that the Irinophore C (TM) formulation is significantly less toxic than irinotecan, used either as a single agent or in combination with 5-fluorouracil, in a rat model of irinotecan-induced gastrointestinal toxicity.
机译:伊立替康是一种水溶性喜树碱衍生物,对大肠癌和小细胞肺癌具有临床活性,目前是与5-氟尿嘧啶联合治疗大肠癌的护理标准。限制使用伊立替康的主要临床问题之一是胃肠道毒性,表现为危及生命的腹泻,据报道,高达45%的治疗患者。此处总结的研究在伊立替康相关胃肠道毒性的大鼠模型中进行了测试,当伊立替康的脂质纳米颗粒制剂Irinophore C(TM)以与未配制的伊立替康相当的剂量给药时,是否减轻了早发性腹泻或后发性腹泻。导致早发性腹泻和迟发性腹泻。具体而言,连续两天静脉内施用170 mg / kg,然后为160 mg / kg的未配制的伊立替康的大鼠在每次给药后经历短暂的早发性腹泻,然后在治疗后4天达到严重的迟发性腹泻高峰。以相同剂量和时间表给药的依琳诺弗C(TM)在任何动物中均不会引起早发或晚发腹泻。当依林诺弗C(TM)与5-氟尿嘧啶联合使用时,也未观察到早发或晚发腹泻。胃肠道的组织病理学分析证实,在以相同剂量给予依里诺菲C(TM)的大鼠中,没有与伊立替康治疗相关的作用。药代动力学分析表明,与未配制的伊立替康相比,给予纳米颗粒制剂的大鼠中伊立替康的全身浓度明显更高。这些结果表明,在依立替康诱导的胃肠道毒性的大鼠模型中,作为单一药剂或与5-氟尿嘧啶组合使用的依诺富特C(TM)制剂的毒性明显低于伊立替康。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号